00241 Overview

Market Performance: The Hang Seng Index (HSI) fell by 570 points (2.1%) to 26,059, while the Hang Seng Tech Index (HSTI) dropped 148 points (2.9%) to 4,989, with a total market turnover of $357.68 billion.

Declining Heavyweights: Major stocks like Xiaomi, Meituan, and Alibaba experienced significant declines, with Xiaomi down 5% and Alibaba down 4.5%, amidst high short selling ratios.

Gainers in the Market: Xinyi Glass and CNOOC were notable gainers, with Xinyi Glass rising 12.4% to a new high, while CNOOC increased by 5.6%.

Volatile Stocks: Several stocks faced sharp declines, including Guofuhee, which plummeted 19.2%, and Dmall, which fell 13.1%, indicating a volatile trading environment.

Market Performance: The Hang Seng Index (HSI) fell by 420 points (1.6%) to 26,209, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.1% and 1.4%, respectively.

Active Heavyweights: Major stocks like Xiaomi, Meituan, and Alibaba saw significant drops, with Xiaomi down 4.6% and Alibaba down 2.7%, amidst high short selling activity.

Notable Movers: Xinyi Glass and CNOOC were standout performers, with Xinyi Glass rising 11.4% to a new high, while several other stocks, including Sunny Optical and HSBC Holdings, faced declines.

Short Selling Trends: The short selling ratios for various stocks were notable, with JD Health and HSBC Holdings showing high short selling activity, indicating bearish sentiment among investors.

Market Performance: The Hang Seng Index (HSI) fell by 384 points (1.4%) to close at 26,381, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.9% and 2.4%, respectively, with a total market turnover of $259.28 billion.

Notable Stock Movements: Major stocks like PING AN, BABA, and TENCENT saw significant declines, with PING AN dropping 4.6% and BABA down 3.6%. Conversely, HKEX and CKI Holdings were among the few gainers, with increases of 0.8% and 4.5%, respectively.

High Short Selling Activity: Several stocks experienced high short selling ratios, particularly ZHONGSHENG HLDG and BEIGENE, which saw declines of 10.8% and 9.2%, respectively, indicating bearish sentiment among investors.

Sector Highlights: The technology and healthcare sectors faced notable losses, with companies like WUXI BIO and XPENG dropping over 5%, while some stocks like FIT HON TENG showed strong gains, increasing by 11.5%.

Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.

Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.

Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.

Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.

Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.

Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.

Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.

Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.

JD Health and Ali Health Performance: Both JD Health and Ali Health reported strong revenue growth last year, with pharmaceutical sales increasing by 20-30%, significantly outpacing the national market growth of only 2%.

Market Share Dynamics: The growth reflects a continuous gain in market share by online platforms over traditional hospital channels, despite a decrease in the number of physical pharmacies.

Broker Ratings and Forecasts: CLSA maintained an Outperform rating for JD Health and raised earnings forecasts, while also increasing target prices for both JD Health and Ali Health, indicating potential upside.

Valuation Insights: HSBC Global Research noted that Ali Health's current valuation has largely accounted for recent AI developments, suggesting limited room for further upside.